EXACERBATIONS AND REAL-WORLD OUTOMES INCLUDING CARDIOPULMONARY EVENTS AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (MITOS: EROS+CP US Study) - EROS+CP (US)

Inclusion Criteria

• -≥ 1 prescription(s) fill for BGF on or following July 24, 2020 (date of BGF approval in the United States)
• -Patients must have evidence a qualifying exacerbation events which, per local or global guidelines, would qualify a patient to have treatment escalated or initiated to triple therapy. The qualifying exacerbation event must occur within the 12-month period preceding the initiation of BGF but occurring on or following local BGF commercial availability (July 24, 2020) and includes either of the following
• -≥ 12 months of continuous health plan enrollment preceding the qualifying index exacerbation event date (‘baseline’ period)
• -≥ 1 day of continuous enrollment following the qualifying index exacerbation date
• -Age ≥ 40 years on the qualifying index exacerbation event